A Global Randomized Multicenter Phase 3 Trial Of JCAR017 Compared To Standard Of Care In Adult Subjects With High-Risk, Second-Line, Transplant-Eligible Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (TRANSFORM).